Show simple item record

dc.contributor.author Klement GL
dc.contributor.author Arkun K
dc.contributor.author Valik D
dc.contributor.author Roffidal T
dc.contributor.author Hashemi A
dc.contributor.author Klement C
dc.contributor.author Carmassi P
dc.contributor.author Rietman E
dc.contributor.author Slaby O
dc.contributor.author Mazanek P
dc.contributor.author Mudry P
dc.contributor.author Kovács, Gábor
dc.contributor.author Kiss C
dc.contributor.author Norga K
dc.contributor.author Konstantinov D
dc.contributor.author Andre N
dc.contributor.author Slavc I
dc.contributor.author Berg HV
dc.contributor.author Kolenova A
dc.contributor.author Kren L
dc.contributor.author Tuma J
dc.contributor.author Skotakova J
dc.contributor.author Sterba J
dc.date.accessioned 2016-10-12T07:29:37Z
dc.date.available 2016-10-12T07:29:37Z
dc.date.issued 2016
dc.identifier 84979620592
dc.identifier.citation pagination=46813-46831; journalVolume=7; journalIssueNumber=29; journalTitle=ONCOTARGET;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/3720
dc.identifier.uri doi:10.18632/oncotarget.9488
dc.description.abstract Research has exposed cancer to be a heterogeneous disease with a high degree of inter-tumoral and intra-tumoral variability. Individual tumors have unique profiles, and these molecular signatures make the use of traditional histology-based treatments problematic. The conventional diagnostic categories, while necessary for care, thwart the use of molecular information for treatment as molecular characteristics cross tissue types.This is compounded by the struggle to keep abreast the scientific advances made in all fields of science, and by the enormous challenge to organize, cross-reference, and apply molecular data for patient benefit. In order to supplement the site-specific, histology-driven diagnosis with genomic, proteomic and metabolomics information, a paradigm shift in diagnosis and treatment of patients is required.While most physicians are open and keen to use the emerging data for therapy, even those versed in molecular therapeutics are overwhelmed with the amount of available data. It is not surprising that even though The Human Genome Project was completed thirteen years ago, our patients have not benefited from the information. Physicians cannot, and should not be asked to process the gigabytes of genomic and proteomic information on their own in order to provide patients with safe therapies. The following consensus summary identifies the needed for practice changes, proposes potential solutions to the present crisis of informational overload, suggests ways of providing physicians with the tools necessary for interpreting patient specific molecular profiles, and facilitates the implementation of quantitative precision medicine. It also provides two case studies where this approach has been used.
dc.relation.ispartof urn:issn:1949-2553
dc.title Future paradigms for precision oncology.
dc.type Journal Article
dc.date.updated 2016-10-06T09:58:17Z
dc.language.rfc3066 en
dc.identifier.mtmt 3084428
dc.identifier.pubmed 27223079
dc.contributor.department SE/AOK/K/II. Sz. Gyermekgyógyászati Klinika
dc.contributor.institution Semmelweis Egyetem


Files in this item

xmlui.dri2xhtml.METS-1.0.onlyFromAllowedIP

View/Open

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account